You can buy or sell GLMD and other stocks, options, ETFs, and crypto commission-free!
Galmed Pharmaceuticals Ltd. Ordinary Shares, also called Galmed Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Tel Aviv, Tel Aviv
52 Week High
52 Week Low
Seeking AlphaMar 14
Galmed Pharmaceuticals Ltd.'s (GLMD) CEO Allen Baharaff on Q4 2018 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q4 2018 Results Earnings Conference Call March 13, 2019 8:30 AM ET Company Participants Paul Arndt - Managing Director, LifeSci Advisors Allen Baharaff - Co-Founder, President, Chief Executive Officer Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Officer Yohai Stenzler - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Adam Walsh - Stifel Ed Arce - H.C. Wainwright Mayank Mamtani - B. Riley Car...
Yahoo FinanceMar 13
Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates
Galmed Pharmaceuticals (GLMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.27 per share a year ago.
PR NewswireMar 13
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
TEL AVIV, Israel, March 13, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today reported financial results for the three and twelve months ended December 31, 2018. The Company will host a conference call and webcast at 08:30 ET today. Business Update Updates on progress...
-$0.13 per share
-$0.18 per share